Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A J Scheen

Showing results (221-230 of 787) with videos related to

Pageof 79
Sort By:
Drugs|September 1, 1997
Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developmentsA J Scheen
Revue Medicale De Liege|November 10, 2022
[Prescribing a SGLT2 inhibitor for treating heart failure without inducing hypoglycaemia]A J Scheen
Revue Medicale De Liege|October 3, 2000
[What's new in the domain of obesity?]A J Scheen
Revue Medicale Suisse|October 28, 2015
[Gliptins, cardiovascular safety and congestive heart failure: state of the art after TECOS]A J Scheen
Diabetes & Metabolism|June 14, 2016
Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diureticsA J Scheen
Revue Medicale De Liege|June 18, 2016
[Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes]A J Scheen
Revue Medicale De Liege|May 5, 2016
[INSULIN GLARGINE 300 U/mL (TOUJEO®)]A J Scheen
Revue Medicale De Liege|January 8, 2016
[EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk]A J Scheen
Revue Medicale De Liege|February 13, 2016
[How I TREAT ... THE ROLE OF DPP-4 INHIBITORS (GLIPTINS) IN THE TREATMENT OF TYPE 2 DIABETES]A J Scheen
Revue Medicale De Liege|April 7, 2022
[About the safety profile of SGLT2 inhibitors]A J Scheen
Pageof 79

Showing results (221-230 of 787) with videos related to

Sort By:
Pageof 79
Drugs|September 1, 1997
Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developmentsA J Scheen
Revue Medicale De Liege|November 10, 2022
[Prescribing a SGLT2 inhibitor for treating heart failure without inducing hypoglycaemia]A J Scheen
Revue Medicale De Liege|October 3, 2000
[What's new in the domain of obesity?]A J Scheen
Revue Medicale Suisse|October 28, 2015
[Gliptins, cardiovascular safety and congestive heart failure: state of the art after TECOS]A J Scheen
Diabetes & Metabolism|June 14, 2016
Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diureticsA J Scheen
Revue Medicale De Liege|June 18, 2016
[Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes]A J Scheen
Revue Medicale De Liege|May 5, 2016
[INSULIN GLARGINE 300 U/mL (TOUJEO®)]A J Scheen
Revue Medicale De Liege|January 8, 2016
[EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk]A J Scheen
Revue Medicale De Liege|February 13, 2016
[How I TREAT ... THE ROLE OF DPP-4 INHIBITORS (GLIPTINS) IN THE TREATMENT OF TYPE 2 DIABETES]A J Scheen
Revue Medicale De Liege|April 7, 2022
[About the safety profile of SGLT2 inhibitors]A J Scheen
Pageof 79